Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)
Executive Summary
The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.
You may also be interested in...
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
Pharma Braces For Potential Landmark Moment For US Drug Price Controls
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category
Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.